This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
ischemic stroke | 493 |
brain injury | 275 |
acute stroke | 232 |
stroke patients | 224 |
neurocritical care | 208 |
care unit | 168 |
acute ischemic | 163 |
subarachnoid hemorrhage | 160 |
stroke care | 147 |
patients admitted | 143 |
status epilepticus | 139 |
traumatic brain | 138 |
intensive care | 138 |
stem cells | 134 |
hospital mortality | 131 |
risk factors | 121 |
cardiac arrest | 121 |
intracerebral hemorrhage | 115 |
cerebral edema | 103 |
mean age | 99 |
coronavirus disease | 98 |
critical care | 93 |
logistic regression | 90 |
critically ill | 87 |
ischaemic stroke | 86 |
poor outcome | 85 |
blood pressure | 82 |
acute respiratory | 82 |
within hours | 77 |
intracranial pressure | 77 |
cerebral ischemia | 77 |
brain death | 77 |
among patients | 75 |
stem cell | 68 |
cerebral artery | 67 |
ill patients | 67 |
respiratory syndrome | 66 |
functional outcome | 65 |
intracranial hemorrhage | 64 |
chart review | 63 |
cohort study | 63 |
atrial fibrillation | 63 |
modified rankin | 62 |
aneurysmal subarachnoid | 60 |
mg dl | 59 |
case series | 58 |
patients treated | 57 |
stroke unit | 55 |
systematic review | 55 |
spinal cord | 54 |
increased risk | 54 |
severe acute | 54 |
mesenchymal stem | 54 |
tbi patients | 53 |
ich patients | 53 |
middle cerebral | 53 |
mechanical ventilation | 53 |
emergency department | 53 |
primary outcome | 51 |
cord uid | 50 |
doc id | 50 |
patients presenting | 50 |
head ct | 50 |
bone marrow | 50 |
rankin scale | 50 |
significant difference | 49 |
mortality rate | 49 |
retrospective cohort | 48 |
midline shift | 48 |
glasgow coma | 47 |
united states | 46 |
ct scan | 46 |
statistically significant | 46 |
severe tbi | 46 |
myocardial infarction | 46 |
patients received | 45 |
large vessel | 45 |
hospital discharge | 45 |
retrospective chart | 45 |
clinical outcomes | 44 |
good outcome | 44 |
two groups | 44 |
blood flow | 44 |
acute brain | 43 |
case report | 43 |
magnetic resonance | 42 |
one patient | 42 |
medical center | 42 |
significantly higher | 42 |
computed tomography | 41 |
stroke risk | 41 |
coma scale | 41 |
patients receiving | 40 |
hemorrhagic stroke | 40 |
adult patients | 40 |
viral infection | 40 |
severe covid | 40 |
year old | 40 |
nervous system | 39 |
clinical trial | 39 |
risk factor | 39 |
brain tissue | 39 |
stroke center | 39 |
external ventricular | 39 |
plasminogen activator | 38 |
delayed cerebral | 38 |
endothelial cells | 38 |
old man | 38 |
study period | 38 |
temperature management | 37 |
neural stem | 37 |
hospitalized patients | 37 |
comprehensive stroke | 37 |
mechanical thrombectomy | 36 |
high risk | 36 |
stroke scale | 36 |
icu los | 36 |
mental status | 36 |
new york | 36 |
inclusion criteria | 35 |
consecutive patients | 35 |
median age | 35 |
clinical trials | 35 |
old male | 35 |
significantly associated | 35 |
ischemic strokes | 34 |
patients without | 34 |
statistical analysis | 34 |
clinical characteristics | 34 |
syndrome coronavirus | 34 |
national institutes | 34 |
first hours | 34 |
refractory status | 34 |
inflammatory response | 33 |
ich score | 33 |
patients undergoing | 33 |
functional outcomes | 33 |
novel coronavirus | 33 |
patient population | 33 |
sah patients | 33 |
symptom onset | 32 |
included patients | 32 |
cerebrovascular disease | 32 |
stroke centers | 32 |
regression analysis | 32 |
medical records | 32 |
patients underwent | 31 |
clinical outcome | 31 |
vessel occlusion | 31 |
retrospective review | 31 |
health stroke | 31 |
patient outcomes | 31 |
stroke admissions | 30 |
functional recovery | 30 |
adverse events | 30 |
odds ratio | 30 |
resonance imaging | 30 |
progenitor cells | 30 |
white matter | 30 |
health care | 30 |
burst suppression | 30 |
tissue plasminogen | 30 |
stroke incidence | 29 |
mm hg | 29 |
observational study | 29 |
transient ischemic | 29 |
hypertonic saline | 29 |
ventricular drain | 29 |
cerebral perfusion | 29 |
independently associated | 29 |
health system | 29 |
stroke symptoms | 29 |
acute care | 28 |
hematoma expansion | 28 |
within days | 28 |
spontaneous ich | 28 |
icu admission | 28 |
healthcare system | 28 |
old female | 28 |
animal models | 28 |
electronic medical | 28 |
poor outcomes | 28 |
central nervous | 28 |
neuro icu | 28 |
therapeutic hypothermia | 28 |
carotid artery | 28 |
ar vr | 28 |
sample size | 27 |
cerebral blood | 27 |
transcranial doppler | 27 |
clinical course | 27 |
ng ml | 27 |
two patients | 27 |
ct head | 27 |
four patients | 27 |
discharged home | 27 |
factors associated | 26 |
respiratory failure | 26 |
icu stay | 26 |
cerebral infarction | 26 |
iv tpa | 26 |
model systems | 26 |
cell survival | 26 |
respiratory distress | 26 |
patient care | 26 |
mcg ml | 26 |
may also | 26 |
care units | 26 |
single center | 26 |
growth factor | 26 |
neurocritically ill | 25 |
dimer levels | 25 |
medical history | 25 |
baseline characteristics | 25 |
ct scans | 25 |
mg kg | 25 |
retrospective study | 25 |
quality improvement | 25 |
mortality rates | 25 |
twice daily | 25 |
median time | 24 |
first days | 24 |
assessed using | 24 |
severe traumatic | 24 |
vessel stroke | 24 |
icu patients | 24 |
significant differences | 24 |
internal carotid | 24 |
mri brain | 24 |
vascular risk | 23 |
large artery | 23 |
adverse effects | 23 |
cerebrospinal fluid | 23 |
hematoma volume | 23 |
data collection | 23 |
glasgow outcome | 23 |
hospital stay | 23 |
social media | 23 |
evd placement | 23 |
stroke units | 23 |
secondary outcomes | 23 |
asah patients | 23 |
multivariate analysis | 23 |
retrospective analysis | 23 |
old woman | 22 |
regression model | 22 |
translational genomics | 22 |
case reports | 22 |
confidence interval | 22 |
cerebral vasospasm | 22 |
care patients | 22 |
stroke treatment | 22 |
control group | 22 |
may increase | 22 |
stroke prevention | 22 |
hours post | 22 |
stroke alert | 22 |
family members | 22 |
identified patients | 22 |
commonly used | 22 |
needle time | 22 |
nt protein | 22 |
intraventricular hemorrhage | 21 |
stroke management | 21 |
diabetes mellitus | 21 |
cell death | 21 |
intracranial hypertension | 21 |
target curve | 21 |
patient characteristics | 21 |
urinary tract | 21 |
higher risk | 21 |
pulmonary embolism | 21 |
higher mortality | 21 |
pilot study | 21 |
kidney injury | 21 |
outcome scale | 21 |
less likely | 21 |
cryptogenic stroke | 21 |
distress syndrome | 21 |
immune response | 21 |
decision making | 21 |
determine whether | 21 |
hypercoagulable state | 21 |
air stroke | 21 |
elevated icp | 21 |
stroke severity | 20 |
mrs score | 20 |
ischemic attack | 20 |
inflammatory cytokines | 20 |
prospectively collected | 20 |
triceps brachii | 20 |
reactive protein | 20 |
retrospectively reviewed | 20 |
prospective studies | 20 |
multivariable logistic | 20 |
targeted temperature | 20 |
artery occlusion | 20 |
basal ganglia | 20 |
new onset | 20 |
temporal lobe | 20 |
posterior circulation | 20 |
hospital admission | 20 |
performed using | 20 |
middle east | 20 |
medical record | 20 |
andexanet alfa | 20 |
stroke alerts | 19 |
stroke onset | 19 |
mass effect | 19 |
total number | 19 |
endovascular treatment | 19 |
higher rates | 19 |
three patients | 19 |
positive patients | 19 |
endothelial dysfunction | 19 |
neurological disorders | 19 |
antiphospholipid antibodies | 19 |
hospital length | 19 |
coronavirus infection | 19 |
adverse drug | 19 |
arrest patients | 19 |
mg twice | 19 |
cytokine storm | 19 |
anterior circulation | 19 |
factor xa | 19 |
stroke cases | 19 |
thromboembolic events | 19 |
controlled trial | 18 |
mean arterial | 18 |
clinical practice | 18 |
hospital day | 18 |
hemorrhagic transformation | 18 |
hospital course | 18 |
recurrent stroke | 18 |
intraparenchymal hemorrhage | 18 |
heart rate | 18 |
past medical | 18 |
limited data | 18 |
patients may | 18 |
multivariate logistic | 18 |
five patients | 18 |
continuous eeg | 18 |
days post | 18 |
outcomes included | 18 |
long term | 18 |
scale score | 18 |
exclusion criteria | 18 |
day mortality | 18 |
malignant cerebral | 18 |
baseline period | 18 |
brain mri | 18 |
arterial pressure | 18 |
significant association | 18 |
high mortality | 18 |
intravenous thrombolysis | 18 |
converting enzyme | 17 |
brain showed | 17 |
major bleeding | 17 |
initial ct | 17 |
analyzed using | 17 |
heart association | 17 |
leading cause | 17 |
neurologic manifestations | 17 |
ischemic brain | 17 |
tertiary care | 17 |
three months | 17 |
ct angiogram | 17 |
worse outcomes | 17 |
clinical deterioration | 17 |
focal cerebral | 17 |
stroke subtypes | 17 |
medical management | 17 |
nt treatment | 17 |
heart failure | 17 |
patient developed | 17 |
groin puncture | 17 |
therapeutic anticoagulation | 17 |
protective equipment | 17 |
subdural hematoma | 17 |
code stroke | 17 |
systemic inflammation | 17 |
pupillary reactivity | 17 |
american heart | 17 |
stroke may | 17 |
may lead | 17 |
hospital complications | 17 |
sided weakness | 17 |
linear regression | 17 |
ich volume | 17 |
neurological deficits | 17 |
significant increase | 17 |
one week | 17 |
presenting feature | 17 |
acute kidney | 17 |
blood cultures | 17 |
neurological symptoms | 17 |
informed consent | 16 |
cell homing | 16 |
study design | 16 |
neurological emergencies | 16 |
may occur | 16 |
following acute | 16 |
recent study | 16 |
small vessel | 16 |
affected forelimb | 16 |
apnea testing | 16 |
patients required | 16 |
per patient | 16 |
acute ischaemic | 16 |
outcome measures | 16 |
time points | 16 |
heart disease | 16 |
thrombotic complications | 16 |
venous thrombosis | 16 |
interquartile range | 16 |
trend towards | 16 |
independent predictors | 16 |
may provide | 16 |
high dose | 16 |
discharge disposition | 16 |
user stroke | 16 |
brain edema | 16 |
healthcare professionals | 16 |
least one | 16 |
neurological complications | 16 |
thrombotic events | 16 |
years old | 16 |
data suggest | 16 |
stroke association | 16 |
care society | 16 |
continuous variables | 15 |
palliative care | 15 |
code strokes | 15 |
poor prognosis | 15 |
studies showed | 15 |
anoxic brain | 15 |
patients included | 15 |
derived factor | 15 |
study showed | 15 |
hemorrhagic strokes | 15 |
significantly lower | 15 |
apnea test | 15 |
grip strength | 15 |
serum chloride | 15 |
treated rats | 15 |
thrombolytic therapy | 15 |
previously reported | 15 |
acute cerebrovascular | 15 |
acute rehabilitation | 15 |
independent predictor | 15 |
cerebral venous | 15 |
thromboembolic complications | 15 |
epileptiform discharges | 15 |
projected curve | 15 |
acute neurological | 15 |
altered mental | 15 |
favorable outcome | 15 |
blood glucose | 15 |
one year | 15 |
stroke among | 15 |
injured patients | 15 |
stroke point | 15 |
eeg monitoring | 15 |
remains unclear | 15 |
clinical variables | 15 |
clinical data | 15 |
sinus thrombosis | 15 |
spontaneous intracerebral | 15 |
year period | 15 |
spot sign | 15 |
vasogenic edema | 15 |
barthel index | 15 |
marrow stem | 15 |
central venous | 14 |
care providers | 14 |
one study | 14 |
emergency medical | 14 |
retrospective observational | 14 |
hyperosmolar therapy | 14 |
neurological manifestations | 14 |
national institute | 14 |
cst axons | 14 |
care setting | 14 |
endothelial progenitor | 14 |
vessel disease | 14 |
cervical spinal | 14 |
better understand | 14 |
poorly understood | 14 |
month follow | 14 |
brain injuries | 14 |
serum sodium | 14 |
vascular endothelial | 14 |
study aims | 14 |
human neural | 14 |
neurological examination | 14 |
organ donation | 14 |
posterior cerebral | 14 |
optic nerve | 14 |
emergency room | 14 |
results suggest | 14 |
collected data | 14 |
neurointensive care | 14 |
patients met | 14 |
clinic referrals | 14 |
enrolled patients | 14 |
disease severity | 14 |
cord injury | 14 |
primary objective | 14 |
venous thromboembolism | 14 |
immune system | 14 |
subdural hemorrhage | 14 |
aneurysmal sah | 14 |
icu length | 14 |
neurostimulant administration | 14 |
tract infection | 14 |
coronary artery | 14 |
observational studies | 14 |
patients showed | 14 |
metabolic acidosis | 14 |
significant reduction | 14 |
potential confounders | 14 |
functional status | 14 |
healthcare providers | 14 |
brain barrier | 14 |
univariate analysis | 14 |
world health | 14 |
skilled nursing | 14 |
patients requiring | 14 |
cell transplantation | 14 |
included studies | 14 |
treatment allocation | 13 |
electrographic seizures | 13 |
respiratory symptoms | 13 |
pupil size | 13 |
increased mortality | 13 |
elevated intracranial | 13 |
neurological outcomes | 13 |
renal disease | 13 |
clinical seizures | 13 |
elderly patients | 13 |
life support | 13 |
eeg patterns | 13 |
units kg | 13 |
cohort studies | 13 |
may improve | 13 |
ulnar nerve | 13 |
time window | 13 |
unfavorable outcome | 13 |
health organization | 13 |
cerebral autoregulation | 13 |
brain ct | 13 |
infarct volume | 13 |
stroke evaluation | 13 |
will also | 13 |
stroke due | 13 |
present study | 13 |
stroke associated | 13 |
critical illness | 13 |
median gcs | 13 |
endothelial cell | 13 |
supplementary material | 13 |
painful stimulation | 13 |
medical treatment | 13 |
two weeks | 13 |
neurological deterioration | 13 |
emergency departments | 13 |
genomic studies | 13 |
mechanically ventilated | 13 |
mcg kg | 13 |
decompressive hemicraniectomy | 13 |
neurological outcome | 13 |
intravascular coagulation | 13 |
calculated using | 13 |
analysis showed | 13 |
review board | 13 |
icp monitoring | 13 |
head showed | 13 |
also found | 13 |
higher rate | 13 |
personal protective | 13 |
affected wrist | 13 |
neurology residents | 13 |
imaging findings | 13 |
admission gcs | 13 |
submitted work | 13 |
nursing facility | 13 |
six months | 13 |
clinical care | 13 |
american stroke | 13 |
post hoc | 13 |
binary logistic | 13 |
trauma center | 13 |
improve outcomes | 13 |
brain imaging | 13 |
york healthcare | 13 |
systolic blood | 13 |
potential adverse | 13 |
normal range | 13 |
hemispheric infarction | 12 |
periodic discharges | 12 |
may result | 12 |
blood cell | 12 |
platelet function | 12 |
stroke mimics | 12 |
increased icp | 12 |
significantly different | 12 |
general population | 12 |
repeat imaging | 12 |
improve outcome | 12 |
growth factors | 12 |
patient days | 12 |
nihss score | 12 |
future studies | 12 |
drug effects | 12 |
east respiratory | 12 |
patients will | 12 |
deep vein | 12 |
poor clinical | 12 |
arterial verapamil | 12 |
lumbar puncture | 12 |
recent studies | 12 |
among stroke | 12 |
following commands | 12 |
prevention clinic | 12 |
patients enrolled | 12 |
primary diagnosis | 12 |
confirmed covid | 12 |
standard deviation | 12 |
organ failure | 12 |
embryonic stem | 12 |
primary endpoint | 12 |
severe cases | 12 |
tract infections | 12 |
horizontal ladder | 12 |
venous sinus | 12 |
neurol doi | 12 |
corticospinal tract | 12 |
ct findings | 12 |
randomized controlled | 12 |
machine learning | 12 |
small sample | 12 |
predictive value | 12 |
ct mri | 12 |
pupillary light | 12 |
hospitalized covid | 12 |
team members | 12 |
vascular imaging | 12 |
intracranial aneurysms | 12 |
significant decrease | 12 |
correlation coefficient | 12 |
previous studies | 12 |
medical services | 12 |
antiepileptic drugs | 12 |
inpatient sample | 12 |
older age | 12 |
outcome group | 12 |
prothrombin complex | 12 |
prospective cohort | 12 |
neurologic outcome | 12 |
time period | 12 |
endovascular therapy | 12 |
disseminated intravascular | 12 |
vein thrombosis | 12 |
institutional review | 12 |
common cause | 12 |
days later | 12 |
perfusion pressure | 12 |
may contribute | 12 |
moyamoya disease | 12 |
comfort care | 12 |
treated patients | 12 |
prospective study | 12 |
time frame | 12 |
nine patients | 12 |
related stroke | 12 |
neurologic injury | 11 |
stroke subtype | 11 |
infarct size | 11 |
european stroke | 11 |
dis doi | 11 |
may benefit | 11 |
demographic data | 11 |
stroke hospitalization | 11 |
stroke physicians | 11 |
patients developed | 11 |
pooled frequency | 11 |
met inclusion | 11 |
large hemispheric | 11 |
neurological injury | 11 |
early mobilization | 11 |
clinical features | 11 |
case fatality | 11 |
statistical analyses | 11 |
among covid | 11 |
stroke registry | 11 |
xa levels | 11 |
based study | 11 |
inpatient mortality | 11 |
target temperature | 11 |
study population | 11 |
refractory se | 11 |
amyloid angiopathy | 11 |
vte prophylaxis | 11 |
medical complications | 11 |
three groups | 11 |
ct showed | 11 |
compared using | 11 |
term outcomes | 11 |
several days | 11 |
hospital los | 11 |
improve patient | 11 |
versus minutes | 11 |
tissue factor | 11 |
stroke therapy | 11 |
vehicle treated | 11 |
measured using | 11 |
per year | 11 |
functional connectivity | 11 |
antiplatelet agents | 11 |
previously healthy | 11 |
marrow stromal | 11 |
may help | 11 |
good functional | 11 |
tissue oxygen | 11 |
cerebrovasc dis | 11 |
propofol infusion | 11 |
weighted imaging | 11 |
coil embolization | 11 |
artery disease | 11 |
motor neurons | 11 |
diffuse cerebral | 11 |
red blood | 11 |
outcome assessment | 11 |
good outcomes | 11 |
stromal cell | 11 |
healthy volunteers | 11 |
adhesion molecules | 11 |
race ethnicity | 11 |
ketamine infusion | 11 |
days following | 11 |
final analysis | 11 |
sip cohort | 11 |
stromal cells | 11 |
brain herniation | 11 |
cerebrovascular events | 11 |
stroke projection | 11 |
left middle | 11 |
stroke team | 11 |
comatose patients | 11 |
final version | 11 |
virtual object | 11 |
eight patients | 11 |
decompressive craniectomy | 11 |
ct angiography | 11 |
neurosurgical intervention | 11 |
nasal cannula | 11 |
neurological exam | 11 |
comfort measures | 11 |
emergency care | 11 |
academic medical | 11 |
comatose survivors | 11 |
stroke code | 11 |
prior studies | 10 |
complex concentrate | 10 |
including stroke | 10 |
grade sah | 10 |
eeg data | 10 |
reverse genomic | 10 |
inhospital mortality | 10 |
prospective observational | 10 |
hospital admissions | 10 |
descriptive statistics | 10 |
patients experienced | 10 |
small number | 10 |
controlled trials | 10 |
virtual objects | 10 |
ten patients | 10 |
without covid | 10 |
icp mmhg | 10 |
known well | 10 |
rat model | 10 |
significant improvement | 10 |
head trauma | 10 |
regression models | 10 |
therapeutic efficacy | 10 |
time periods | 10 |
automated pupillometry | 10 |
inpatient rehabilitation | 10 |
hemostatic efficacy | 10 |
platelet count | 10 |
ventriculoperitoneal shunt | 10 |
longer icu | 10 |
intravenous tissue | 10 |
showed diffuse | 10 |
northern california | 10 |
one month | 10 |
cervical spine | 10 |
oral anticoagulant | 10 |
encephalopathy syndrome | 10 |
comorbidity index | 10 |
high incidence | 10 |
public health | 10 |
stroke organisation | 10 |
corpus callosum | 10 |
renal failure | 10 |
rat brain | 10 |
surgical decompression | 10 |
neurosciences intensive | 10 |
multivariable analysis | 10 |
cerebral hemodynamics | 10 |
respiratory tract | 10 |
exact test | 10 |
retrospectively analyzed | 10 |
sodium chloride | 10 |
scale scores | 10 |
cardiovascular disease | 10 |
right mca | 10 |
kg min | 10 |
infection may | 10 |
risk patients | 10 |
last known | 10 |
many patients | 10 |
reversible encephalopathy | 10 |
neurostimulant initiation | 10 |
reverse translation | 10 |
presentation time | 10 |
using spss | 10 |
mouse model | 10 |
cerebral arteries | 10 |
neuroscience icu | 10 |
apache ii | 10 |
york city | 10 |
data regarding | 10 |
sodium levels | 10 |
controlled release | 10 |
traditional risk | 10 |
nerve sheath | 10 |
readmission rate | 10 |
important role | 10 |
contemporary controls | 10 |
average age | 10 |
good neurological | 10 |
body temperature | 10 |
human disease | 10 |
following tbi | 10 |
patient demographics | 10 |
regression analyses | 10 |
previously published | 10 |
provincial lockdown | 10 |
phase iii | 10 |
per day | 10 |
assess whether | 10 |
chain reaction | 10 |
air pollution | 10 |
baseline data | 10 |
transplanted cells | 10 |
outcome measure | 10 |
intellectual content | 10 |
increased incidence | 10 |
younger age | 10 |
vital signs | 10 |
bypass surgery | 10 |
fxa activity | 10 |
airway protection | 10 |
clinical suspicion | 10 |
patients diagnosed | 10 |
continuous infusion | 10 |
two days | 10 |
resource utilization | 10 |
conducted using | 10 |
received iv | 10 |
light reflex | 10 |
ml min | 10 |
care population | 10 |
flow nasal | 10 |
specific gravity | 10 |
mortality among | 10 |
limited resources | 10 |
three days | 10 |
center study | 10 |
cell adhesion | 10 |
point projection | 10 |
wide association | 10 |
excluded patients | 10 |
literature review | 10 |
air strokes | 10 |
patients hospitalized | 10 |
many countries | 10 |
admission rate | 10 |
low threshold | 10 |
barre syndrome | 10 |
onset seizures | 10 |
successful recanalization | 10 |
tract hemorrhages | 10 |
analyses will | 10 |
stroke organization | 9 |
human nt | 9 |
stroke services | 9 |
fatality rate | 9 |
higher incidence | 9 |
code status | 9 |
intracerebral haemorrhage | 9 |
primary stroke | 9 |
mimicry projection | 9 |
possible mechanisms | 9 |
derived stem | 9 |
early management | 9 |
gold standard | 9 |
oxygen saturation | 9 |
kidney disease | 9 |
mortality associated | 9 |
following day | 9 |
cognitive impairment | 9 |
neurologic emergencies | 9 |
cell migration | 9 |
underwent continuous | 9 |
initial gcs | 9 |
igf levels | 9 |
ct score | 9 |
polymerase chain | 9 |
stroke program | 9 |
tranexamic acid | 9 |
one case | 9 |
identified using | 9 |
von willebrand | 9 |
multimodal monitoring | 9 |
coma recovery | 9 |
convulsive status | 9 |
severe infection | 9 |
stroke model | 9 |
diabetes insipidus | 9 |
gene expression | 9 |
hemodynamic instability | 9 |
ms ms | 9 |
clinical effectiveness | 9 |
identify patients | 9 |
pilot testing | 9 |
world stroke | 9 |
interferon gamma | 9 |
racial disparities | 9 |
included age | 9 |
increasingly used | 9 |
young patients | 9 |
blood pressures | 9 |
outside hospital | 9 |
surgical intervention | 9 |
high morbidity | 9 |
baseline demographics | 9 |
including patients | 9 |
functional improvement | 9 |
medical care | 9 |
median ich | 9 |
randomized clinical | 9 |
head injury | 9 |
association american | 9 |
mature nt | 9 |
raised icp | 9 |
clinical improvement | 9 |
coronavirus pneumonia | 9 |
posterior reversible | 9 |
receiver operating | 9 |
association study | 9 |
digital subtraction | 9 |
chest ct | 9 |
university hospital | 9 |
adult inpatients | 9 |
findings suggest | 9 |
study shows | 9 |
improves outcome | 9 |
associated ich | 9 |
coma score | 9 |
scoring system | 9 |
severe sars | 9 |
patient underwent | 9 |
retrospectively identified | 9 |
rankin score | 9 |
anticoagulation therapy | 9 |
venous access | 9 |
stroke outcome | 9 |
ischemic attacks | 9 |
hyperacute stroke | 9 |
current pandemic | 9 |
phe volume | 9 |
eight weeks | 9 |
wilcoxon rank | 9 |
quantitative eeg | 9 |
amino acid | 9 |
useful tool | 9 |
previous stroke | 9 |
patients aged | 9 |
gcs score | 9 |
molecular weight | 9 |
sheath diameter | 9 |
central line | 9 |
infective endocarditis | 9 |
within one | 9 |
ethics committee | 9 |
lung injury | 9 |
dedicated neurocritical | 9 |
septic shock | 9 |
may cause | 9 |
severe disease | 9 |
strongly associated | 9 |
african american | 9 |
vascular injury | 9 |
ct brain | 9 |
multicenter clinical | 9 |
common complication | 9 |
neuromuscular blockade | 9 |
side effects | 9 |
clinical indications | 9 |
prothrombin time | 9 |
clinical presentation | 9 |
statistical significance | 9 |
patient presented | 9 |
cerebral amyloid | 9 |
basilar artery | 9 |
genomic translation | 9 |
drain placement | 9 |
spontaneous circulation | 9 |
subarachnoid haemorrhage | 9 |
case highlights | 9 |
admission sbp | 9 |
neuroscience intensive | 9 |
study using | 8 |
academic hospital | 8 |
infectious diseases | 8 |
flow diversion | 8 |
endovascular intervention | 8 |
left sided | 8 |
rodent models | 8 |
artery territory | 8 |
significant morbidity | 8 |
therapeutic interventions | 8 |
extubation failure | 8 |
stroke disappearance | 8 |
intracranial aneurysm | 8 |
neurosurgical patients | 8 |
perihematomal edema | 8 |
blood vessels | 8 |
vertebral artery | 8 |
current guidelines | 8 |
vast majority | 8 |
data will | 8 |
motor function | 8 |
categorical variables | 8 |
infarct cavity | 8 |
acute subdural | 8 |
patients within | 8 |
resonance angiography | 8 |
baffling case | 8 |
multimodality monitoring | 8 |
oxidative stress | 8 |
patients presented | 8 |
subtraction angiography | 8 |
patient outcome | 8 |
repeat head | 8 |
primary efficacy | 8 |
infarcted heart | 8 |
patient populations | 8 |
care medicine | 8 |
patients died | 8 |
well tolerated | 8 |
transfer time | 8 |
spine surgery | 8 |
derived mesenchymal | 8 |
social network | 8 |
neurologic outcomes | 8 |
plasma exchange | 8 |
less affected | 8 |
neurologic deterioration | 8 |
somatosensory cortex | 8 |
financial relationships | 8 |
surgical clipping | 8 |
seven studies | 8 |
early mobility | 8 |
obstructive hydrocephalus | 8 |
model system | 8 |
global cerebral | 8 |
stroke genetics | 8 |
super refractory | 8 |
patient received | 8 |
pandemic date | 8 |
medical education | 8 |
within minutes | 8 |
arterial blood | 8 |
left mca | 8 |
sensorimotor recovery | 8 |
months post | 8 |
center retrospective | 8 |
rapid response | 8 |
secondary stroke | 8 |
practice changes | 8 |
time series | 8 |
improve functional | 8 |
post injury | 8 |
frontal lobe | 8 |
cerebral herniation | 8 |
implementation group | 8 |
international stroke | 8 |
reperfusion therapies | 8 |
socioeconomic status | 8 |
hypoxic ischemic | 8 |
individual basis | 8 |
independent risk | 8 |
acute severe | 8 |
significantly reduced | 8 |
stroke cerebrovasc | 8 |
admission nihss | 8 |
causal relationship | 8 |
evidence suggests | 8 |
younger patients | 8 |
ischemic heart | 8 |
stroke mimicry | 8 |
retrospective case | 8 |
antiepileptic drug | 8 |
abnormal coagulation | 8 |
left ventricular | 8 |
occlusive disease | 8 |
higher mean | 8 |
enteral antihypertensive | 8 |
lower rate | 8 |
icp management | 8 |
casualty department | 8 |
puncture time | 8 |
phase trial | 8 |
month period | 8 |
family engagement | 8 |
timely manner | 8 |
stroke mortality | 8 |
goal sodium | 8 |
hong kong | 8 |
willebrand factor | 8 |
evd placed | 8 |
seizure control | 8 |
annual meeting | 8 |
minutes post | 8 |
iic patterns | 8 |
nitric oxide | 8 |
antiplatelet therapy | 8 |
missing data | 8 |
underwent evt | 8 |
therapeutic targets | 8 |
refractory icp | 8 |
seizure activity | 8 |
hemorrhagic complications | 8 |
right hemisphere | 8 |
protected code | 8 |
medical staff | 8 |
gene polymorphism | 8 |
chronic kidney | 8 |
transfer patients | 8 |
repeat ct | 8 |
pain scores | 8 |
adjunctive therapy | 8 |
signi cantly | 8 |
nationwide inpatient | 8 |
may play | 8 |
outcomes following | 8 |
higher levels | 8 |
west nile | 8 |
sum test | 8 |
daily doses | 8 |
seizure prophylaxis | 8 |
training program | 8 |
stroke trials | 8 |
mri revealed | 8 |
stage renal | 8 |
weight heparin | 8 |
rare case | 8 |
corresponding author | 8 |
ischemic rat | 8 |
collateral effect | 8 |
coagulation parameters | 8 |
lower rates | 8 |
term functional | 8 |
anesthetic agents | 8 |
neurological recovery | 8 |
mean regx | 8 |
random forest | 8 |
adjusted odds | 8 |
rank sum | 8 |
clinically significant | 8 |
eeg background | 8 |
per week | 8 |
icu needs | 8 |
plasma igf | 8 |
stroke rates | 8 |
laboratory data | 8 |
gad ab | 8 |
hospital acquired | 8 |
worse functional | 8 |
imaging revealed | 8 |
cell therapy | 8 |
authors declare | 8 |
aha asa | 8 |
systolic bp | 8 |
level trauma | 8 |
including ischemic | 8 |
neural progenitor | 8 |
six hours | 8 |
ejection fraction | 8 |
multimodal approach | 8 |
immediate post | 8 |
pediatric patients | 8 |
onsd measurement | 8 |
catheter days | 8 |
confirmed cases | 8 |
new coronavirus | 8 |
dose ta | 8 |
may present | 8 |
arrival time | 8 |
fecal management | 8 |
despite aggressive | 8 |
prospectively enrolled | 8 |
mild strokes | 8 |
emergency medicine | 8 |
stroke volume | 8 |
treatment caused | 8 |
future work | 8 |
neurological icu | 8 |
intracranial hypotension | 7 |
higher proportion | 7 |
institutional protocol | 7 |
patients infected | 7 |
txa administration | 7 |
requiring icu | 7 |
analysis included | 7 |
stroke pathways | 7 |
almost half | 7 |
neurologic status | 7 |
family history | 7 |
analysis plan | 7 |
chloride concentration | 7 |
nurse practitioners | 7 |
stroke teams | 7 |
creative commons | 7 |
mouse models | 7 |
mg daily | 7 |
mean values | 7 |
square test | 7 |
acute traumatic | 7 |
receptor antagonist | 7 |
smooth muscle | 7 |
guidelines recommend | 7 |
complication rates | 7 |
brain code | 7 |
neuronal death | 7 |
increased disability | 7 |
perfusion imaging | 7 |
data points | 7 |
patients discharged | 7 |
ceeg monitoring | 7 |
electronic health | 7 |
mg day | 7 |
system involvement | 7 |
ill icu | 7 |
practice guidelines | 7 |
early rehabilitation | 7 |
may reflect | 7 |
tube feeding | 7 |
sleep disruption | 7 |
neuroimaging findings | 7 |
pupil reactivity | 7 |
patient safety | 7 |
physical examination | 7 |
clinical evidence | 7 |
covid patients | 7 |
health record | 7 |
brainstem reflexes | 7 |
study periods | 7 |
vasospasm following | 7 |
significant changes | 7 |
cerebral circulation | 7 |
nsicu patients | 7 |
deep venous | 7 |
hyperexcitable patterns | 7 |
iv rt | 7 |
neurogenic shock | 7 |
significantly reduce | 7 |
month functional | 7 |
reactive oxygen | 7 |
high grade | 7 |
stroke database | 7 |
discharge mrs | 7 |
also compared | 7 |
brain parenchyma | 7 |
hospital care | 7 |
following aneurysmal | 7 |
xa inhibitor | 7 |
vascular endothelium | 7 |
left frontal | 7 |
unit admissions | 7 |
male presented | 7 |
may reduce | 7 |
cerebrovascular accidents | 7 |
health services | 7 |
several limitations | 7 |
initial dose | 7 |
general hospital | 7 |
burr hole | 7 |
vpa levels | 7 |
neurotrophic factor | 7 |
cell recruitment | 7 |
clinically relevant | 7 |
anterior cerebral | 7 |
blood tests | 7 |
larger prospective | 7 |
least hours | 7 |
national level | 7 |
brain atrophy | 7 |
ventilated patients | 7 |
confidence intervals | 7 |
medical attention | 7 |
ocular ultrasound | 7 |
supportive care | 7 |
performance category | 7 |
severe brain | 7 |
care systems | 7 |
defi ned | 7 |
phase i | 7 |
initial head | 7 |
cerebral performance | 7 |
health systems | 7 |
neurosurgical procedures | 7 |
nonconvulsive seizures | 7 |
jugular bulb | 7 |
high suspicion | 7 |
care facility | 7 |
ais patients | 7 |
may serve | 7 |
complication following | 7 |
longer duration | 7 |
intravenous alteplase | 7 |
one day | 7 |
vte bundle | 7 |
organ procurement | 7 |
gamma gene | 7 |
genome sequencing | 7 |
neurostimulant medications | 7 |
severe infections | 7 |
every hours | 7 |
lower comorbidity | 7 |
acute tbi | 7 |
preliminary data | 7 |
mean number | 7 |
prognostic models | 7 |
age years | 7 |
bleed day | 7 |
studies reported | 7 |
hypoxia preconditioning | 7 |
sample sizes | 7 |
urine specific | 7 |
severe symptoms | 7 |
management protocols | 7 |
care ultrasound | 7 |
sip orders | 7 |
blood cells | 7 |
positive results | 7 |
hypertonic nacl | 7 |
patients per | 7 |
time taken | 7 |
prothrombotic state | 7 |
following cardiac | 7 |
laboratory markers | 7 |
hospital transport | 7 |
eeg showed | 7 |
current study | 7 |
death declaration | 7 |
infectious complications | 7 |
imaging data | 7 |
study including | 7 |
mca territory | 7 |
membrane oxygenation | 7 |
imaging showed | 7 |
symptoms onset | 7 |
ct revealed | 7 |
dwi lesions | 7 |
five days | 7 |
poor functional | 7 |
current covid | 7 |
acute non | 7 |
infusion duration | 7 |
neurological emergency | 7 |
arterial thromboembolic | 7 |
experimental studies | 7 |
nihss scores | 7 |
ganglia ich | 7 |
clinical significance | 7 |
hounsfield unit | 7 |
cardiovascular events | 7 |
community hospitals | 7 |
di cult | 7 |
focal neurological | 7 |
secondary brain | 7 |
novel oral | 7 |
target curves | 7 |
recent years | 7 |
overall mortality | 7 |
reperfusion therapy | 7 |
early tracheostomy | 7 |
kg hr | 7 |
catchment area | 7 |
systematic reviews | 7 |
diagnostic work | 7 |
reference range | 7 |
air drawing | 7 |
phong projection | 7 |
evd insertion | 7 |
falling stroke | 7 |
mesial temporal | 7 |
adverse effect | 7 |
times higher | 7 |
diff erences | 7 |
iv brv | 7 |
previous year | 7 |
mean duration | 7 |
adhesive patch | 7 |
laboratory values | 7 |
antibiotic therapy | 7 |
prior ich | 7 |
stroke caused | 7 |
may include | 7 |
ischemic mice | 7 |
male gender | 7 |
function testing | 7 |
potential solutions | 7 |
wilcoxon signed | 7 |
nationally representative | 7 |
patients developing | 7 |
stroke within | 7 |
patients survived | 7 |
rhythmic delta | 7 |
patient data | 7 |
early post | 7 |
clot formation | 7 |
analysis using | 7 |
healthy subjects | 7 |
genetic risk | 7 |
ct imaging | 7 |
following stroke | 7 |
minutes pre | 7 |
neurological worsening | 7 |
alert volumes | 7 |
observational cohort | 7 |
hunt hess | 7 |
acute phase | 7 |
right frontal | 7 |
behavioral recovery | 7 |
stroke recovery | 7 |
minimally invasive | 7 |
four cases | 7 |
subgroup analysis | 7 |
study aimed | 7 |
nmes hpro | 7 |
laboratory findings | 7 |
national stroke | 7 |
early clamp | 7 |
stroke patient | 7 |
mayo clinic | 7 |
functional mri | 7 |
left side | 7 |
cerebral oxygen | 7 |
per month | 7 |
takotsubo cardiomyopathy | 7 |
hemorrhage patients | 7 |
csf diversion | 7 |
electrical stimulation | 7 |
cognitive function | 7 |
subcortical myoclonus | 7 |
acute myocardial | 7 |
marrow mesenchymal | 7 |
primary analysis | 7 |
demographic characteristics | 7 |
cardiac catheterization | 7 |
early brain | 7 |
six patients | 7 |
respiratory system | 7 |
stroke type | 7 |
lower mortality | 7 |
received thrombolysis | 7 |
clamp trial | 7 |
injury patients | 7 |
peripheral blood | 7 |
acute management | 7 |
restricted diffusion | 7 |
andexanet bolus | 7 |
remained stable | 7 |
oxygen species | 7 |
systemic inflammatory | 7 |
criteria included | 7 |
facial droop | 7 |
median mrs | 7 |
ct demonstrated | 7 |
delta activity | 7 |
intravenous immunoglobulin | 7 |
translational research | 7 |
novel therapeutic | 7 |
two cases | 7 |
study suggests | 7 |
outcomes among | 7 |
contrast extravasation | 7 |
sectional survey | 6 |
mild stroke | 6 |
total patients | 6 |
iron oxide | 6 |
relative risk | 6 |
one neurologist | 6 |
workup revealed | 6 |
ischemic injury | 6 |
vehicle group | 6 |
medication administration | 6 |
remains unknown | 6 |
ketosis prone | 6 |
nmb group | 6 |
stroke remains | 6 |
rbc transfusions | 6 |
projected curves | 6 |
appropriate treatment | 6 |
sequential organ | 6 |
term disability | 6 |
learning methods | 6 |
natural history | 6 |
admission rates | 6 |
among survivors | 6 |
blinded outcome | 6 |
protection equipment | 6 |
white blood | 6 |
air emboli | 6 |
impaired cerebral | 6 |
antimicrobial therapy | 6 |
ich severity | 6 |
regional stroke | 6 |
medical research | 6 |
gene therapy | 6 |
surrogate decision | 6 |
effective care | 6 |
left posterior | 6 |
signifi cant | 6 |
ensoetm recipients | 6 |
thromboplastin time | 6 |
tissue oxygenation | 6 |
mean difference | 6 |
data analysis | 6 |
complications associated | 6 |
previously described | 6 |
oral anticoagulants | 6 |
significant number | 6 |
glioblastoma multiforme | 6 |
may impact | 6 |
transient ischaemic | 6 |
brain revealed | 6 |
standardized management | 6 |
reversal agent | 6 |
vs aspirin | 6 |
charlson comorbidity | 6 |
artery atherosclerosis | 6 |
precursor cells | 6 |
blood loss | 6 |
may need | 6 |
outcomes including | 6 |
auc roc | 6 |
patients often | 6 |
intracranial atherosclerosis | 6 |
therapeutic development | 6 |
following spine | 6 |
serious complications | 6 |
initial presentation | 6 |
clinical predictors | 6 |
obese patients | 6 |
aggressive care | 6 |
serotonin syndrome | 6 |
case control | 6 |
journal club | 6 |
financial support | 6 |
deceased patients | 6 |
lymphocyte ratio | 6 |
disease control | 6 |
also showed | 6 |
significantly improved | 6 |
european countries | 6 |
left hemiparesis | 6 |
hypoxic preconditioning | 6 |
behavioural testing | 6 |
expressive aphasia | 6 |
low gcs | 6 |
black patients | 6 |
severe stroke | 6 |
admission ct | 6 |
studies suggest | 6 |
stroke council | 6 |
gene polymorphisms | 6 |
early mortality | 6 |
female ratio | 6 |
mr imaging | 6 |
randomised controlled | 6 |
antithrombotic therapy | 6 |
antimicrobial prophylaxis | 6 |
secondary outcome | 6 |
activated partial | 6 |
frontal lobes | 6 |
failure assessment | 6 |
lactic acid | 6 |
hematoma evacuation | 6 |
management protocol | 6 |
death within | 6 |
vs poor | 6 |
claims data | 6 |
radiological findings | 6 |
motor response | 6 |
clinical response | 6 |
clinical utility | 6 |
evoked potentials | 6 |
hospitalization rates | 6 |
potentially useful | 6 |
major ht | 6 |
large vessels | 6 |
time spent | 6 |
point likert | 6 |
global burden | 6 |
icu days | 6 |
endpoints included | 6 |
unfavorable outcomes | 6 |
kg day | 6 |
cns vasculitis | 6 |
cerebellar ich | 6 |
multiple sclerosis | 6 |
consensus statement | 6 |
lmwh vs | 6 |
glucose level | 6 |
shared decision | 6 |
factor prothrombin | 6 |
diffusion restriction | 6 |
diagnosis codes | 6 |
gastrostomy tube | 6 |
brain biopsy | 6 |
haemorrhagic transformation | 6 |
first day | 6 |
ill tbi | 6 |
potential therapeutic | 6 |
caregiver notes | 6 |
treatment groups | 6 |
tissue injury | 6 |
neurologic disease | 6 |
survey results | 6 |
multiple linear | 6 |
ncc patients | 6 |
immune responses | 6 |
mrs scores | 6 |
cns infection | 6 |
endovascular coiling | 6 |
inpatient hospice | 6 |
medical conditions | 6 |
trend toward | 6 |
serum levels | 6 |
sudden onset | 6 |
sympathetic storming | 6 |
cortical stroke | 6 |
effects model | 6 |
iv antibiotics | 6 |
dci risk | 6 |
acute hospitalization | 6 |
two studies | 6 |
controlled studies | 6 |
brain lesions | 6 |
malignant edema | 6 |
three cases | 6 |
nyu langone | 6 |
acute sci | 6 |
secondary injury | 6 |
human embryonic | 6 |
neurotrophic factors | 6 |
seven days | 6 |
income countries | 6 |
cerebral arterial | 6 |
strokes may | 6 |
stroke centres | 6 |
diffuse astrocytoma | 6 |
patient died | 6 |
retrospectively collected | 6 |
constriction velocity | 6 |
icp elevation | 6 |
patients whose | 6 |
stroke discharges | 6 |
free vpa | 6 |
major complication | 6 |
care settings | 6 |
cascade initiative | 6 |
cold allodynia | 6 |
human genomic | 6 |
prognostic information | 6 |
left eye | 6 |
clinical application | 6 |
sich patients | 6 |
may affect | 6 |
infection control | 6 |
adverse event | 6 |
postoperative di | 6 |
creatinine clearance | 6 |
piv placement | 6 |
meningioma resection | 6 |
also reported | 6 |
fluid balance | 6 |
broad spectrum | 6 |
direct co | 6 |
vegetative state | 6 |
neural network | 6 |
severe strokes | 6 |
lower gcs | 6 |
elevation myocardial | 6 |
cov positive | 6 |
data elements | 6 |
nt treated | 6 |
surgical interventions | 6 |
real time | 6 |
contrast ct | 6 |
may require | 6 |
neurological monitoring | 6 |
stroke groups | 6 |
severe disability | 6 |
retrospective data | 6 |
phase ii | 6 |
partial thromboplastin | 6 |
stroke protocol | 6 |
sip cohorts | 6 |
cardiogenic shock | 6 |
older patients | 6 |
sdh patients | 6 |
median nihss | 6 |
best practices | 6 |
continuous electroencephalography | 6 |
maximum serum | 6 |
international panel | 6 |
urinary catheter | 6 |
epileptiform activity | 6 |
life threatening | 6 |
di erent | 6 |
previous study | 6 |
delayed treatment | 6 |
healthcare workers | 6 |
emergency neurological | 6 |
focal deficits | 6 |
clinical research | 6 |
cerebral hemorrhage | 6 |
subgroup analyses | 6 |
cranial nerve | 6 |
received intravenous | 6 |
common causes | 6 |
developed acute | 6 |
vascular lesion | 6 |
rotterdam ct | 6 |
pupillary parameters | 6 |
million people | 6 |
noncanceled stroke | 6 |
petrous ica | 6 |
widespread testing | 6 |
first weeks | 6 |
grade subarachnoid | 6 |
cerebral infarcts | 6 |
significantly increased | 6 |
study protocol | 6 |
ex vivo | 6 |
stroke doi | 6 |
therapeutic potential | 6 |
brainstem hemorrhage | 6 |
urgent stroke | 6 |
suspected stroke | 6 |
high levels | 6 |
endotracheal intubation | 6 |
response rate | 6 |
catheter associated | 6 |
posterior fossa | 6 |
cerebrovascular diseases | 6 |
unconscious patients | 6 |
expression levels | 6 |
infrared spectroscopy | 6 |
multiple logistic | 6 |
therapeutic window | 6 |
angiogram showed | 6 |
aspiration pneumonia | 6 |
alpha chloralose | 6 |
pa patients | 6 |
improvement project | 6 |
radiolabelled nt | 6 |
neurologic intensive | 6 |
vascular disease | 6 |
one third | 6 |
body weight | 6 |
particularly among | 6 |
median nerve | 6 |
prognostic value | 6 |
brain temperature | 6 |
neurological life | 6 |
tumor necrosis | 6 |
referring hospital | 6 |
anoxic injury | 6 |
historical controls | 6 |
pressure monitoring | 6 |
hoc analysis | 6 |
invasive icp | 6 |
group compared | 6 |
control points | 6 |
dead patients | 6 |
viral infections | 6 |
neurologic exam | 6 |
stroke points | 6 |
affected hemisphere | 6 |
cerebral glucopenia | 6 |
different levels | 6 |
brain damage | 6 |
ischemic damage | 6 |
studies demonstrated | 6 |
statistical power | 6 |
wlds activity | 6 |
internal jugular | 6 |
first case | 6 |
neurological conditions | 6 |
imaging studies | 6 |
continuous data | 6 |
tcd cus | 6 |
early ct | 6 |
peak plasma | 6 |
high frequency | 6 |
associated urinary | 6 |
central lines | 6 |
longer time | 6 |
significantly worse | 6 |
angiography suite | 6 |
four weeks | 6 |
respondents reported | 6 |
intracranial monitoring | 6 |
factors related | 6 |
progenitor cell | 6 |
significant risk | 6 |
phe expansion | 6 |
mri scans | 6 |
left temporal | 6 |
little data | 6 |
necrosis factor | 6 |
first study | 6 |
apache iii | 6 |
aetiological study | 6 |
screening tool | 6 |
neurological intensive | 6 |
eligibility criteria | 6 |
ventricular drainage | 6 |
cell count | 6 |
prognostic uncertainty | 6 |
descriptive analysis | 6 |
identifying patients | 6 |
prone diabetes | 6 |
poor neurological | 6 |
intravenous therapy | 6 |
well established | 6 |
dilated pupils | 6 |
aneurysm treatment | 6 |
brain tumor | 6 |
jugular vein | 6 |
response eeg | 6 |
eeg system | 6 |
good vs | 6 |
sustained icp | 6 |
racial disparity | 6 |
endovascular thrombectomy | 6 |
following sah | 6 |
thrombus formation | 6 |
optimal timing | 6 |
lc ms | 6 |
classified according | 6 |
recombinant tissue | 6 |
stroke without | 6 |
immune cells | 6 |
seizure detection | 6 |
readmission scores | 6 |
diffusion weighted | 6 |
gcs scores | 6 |
icp values | 6 |
procurement organization | 6 |
gi disorders | 6 |
retrospectively evaluated | 6 |
mild tbi | 6 |
neurologic examination | 6 |
traumatic intracranial | 6 |
pta duration | 6 |
superparamagnetic iron | 6 |
injury requiring | 6 |
icp waveform | 6 |
often used | 6 |
stroke admission | 6 |
artery ischaemic | 6 |
one hour | 6 |
nih stroke | 6 |
new dwi | 6 |
related ich | 6 |
dose steroids | 6 |
potential cause | 6 |
pupil index | 6 |
local plane | 6 |
cns infections | 6 |
hyaluronic acid | 6 |
interprofessional team | 6 |
serial ct | 6 |
level data | 5 |
clinical exam | 5 |
prolonged icu | 5 |
increased use | 5 |
admitting diagnosis | 5 |
study sought | 5 |
significant impact | 5 |
last seen | 5 |
secondary objectives | 5 |
gcse group | 5 |
cerebral angiography | 5 |
secondary prevention | 5 |
clinical pathway | 5 |
cervical instability | 5 |
subsequently developed | 5 |
spoke system | 5 |
stroke study | 5 |
interictal continuum | 5 |
cases per | 5 |
decision tree | 5 |
often require | 5 |
sofa score | 5 |
favorable functional | 5 |
microsoft excel | 5 |
whole blood | 5 |
diffusion coefficient | 5 |
neuroinvasive disease | 5 |
mi mi | 5 |
improved significantly | 5 |
vascular events | 5 |
successfully treated | 5 |
fold increase | 5 |
stroke van | 5 |
acute intracranial | 5 |
transient focal | 5 |
therapeutic implications | 5 |
three times | 5 |
based therapy | 5 |
cell types | 5 |
severe adverse | 5 |
significantly correlated | 5 |
without craniectomy | 5 |
stroke systems | 5 |
mstbi patients | 5 |
ventilator associated | 5 |
low rate | 5 |
lesion volume | 5 |
feeding tube | 5 |
hypertensive infusions | 5 |
acute onset | 5 |
traumatic ich | 5 |
patient presenting | 5 |
rna expression | 5 |
osmolality ratio | 5 |
university health | 5 |
nccu qi | 5 |
hierarchical model | 5 |
patients following | 5 |
therapeutic target | 5 |
therapeutic aptt | 5 |
complications including | 5 |
communicating artery | 5 |
similar results | 5 |
case describes | 5 |
external validation | 5 |
intraventricular milrinone | 5 |
young adults | 5 |
increasing evidence | 5 |
last years | 5 |
coronavirus infections | 5 |
important cause | 5 |
vascular malformations | 5 |
first step | 5 |
refractory intracranial | 5 |
good clinical | 5 |
cerebellar artery | 5 |
goc discussions | 5 |
continuous intravenous | 5 |
enrolled subjects | 5 |
cerebrovascular complications | 5 |
malignant middle | 5 |
sdh evacuation | 5 |
medical comorbidities | 5 |
retrospective evaluation | 5 |
month outcome | 5 |
subarachnoid space | 5 |
sofa scores | 5 |
internal medicine | 5 |
neural precursor | 5 |
left atrial | 5 |
available data | 5 |
cerebral hemispheres | 5 |
decreased significantly | 5 |
tpa administration | 5 |
treatment decisions | 5 |
outcome prediction | 5 |
tissue engineering | 5 |
cerebral angiogram | 5 |
retrospective nature | 5 |
improved outcomes | 5 |
prolonged hospitalization | 5 |
apparent diffusion | 5 |
pulmonary edema | 5 |
seizure burden | 5 |
polygenic risk | 5 |
significantly greater | 5 |
care training | 5 |
requiring intubation | 5 |
aed treatment | 5 |
angiography revealed | 5 |
cerebral injury | 5 |
higher prevalence | 5 |
inadvertent external | 5 |
care consultation | 5 |
elevated serum | 5 |
healthcare systems | 5 |
sustained release | 5 |
time limit | 5 |
good neurologic | 5 |
significantly longer | 5 |
hypercoagulability secondary | 5 |
staff satisfaction | 5 |
highly variable | 5 |
autonomic instability | 5 |
higher percentage | 5 |
cox proportional | 5 |
twelve patients | 5 |
another study | 5 |
early phase | 5 |
acute ich | 5 |
correlation coefficients | 5 |
new eas | 5 |
treatment options | 5 |
cells modified | 5 |
within three | 5 |
also observed | 5 |
reversal guideline | 5 |
presenting symptom | 5 |
standardize care | 5 |
outcome data | 5 |
icp control | 5 |
angiotensin ii | 5 |
quantitative pupillometry | 5 |
recent report | 5 |
early seizures | 5 |
avoid unnecessary | 5 |
cerebral vessel | 5 |
clinical history | 5 |
neurologic recovery | 5 |
obtained within | 5 |
skeletal muscle | 5 |
analysis revealed | 5 |
stroke data | 5 |
demographic information | 5 |
per minute | 5 |
plasma osmolality | 5 |
lower levels | 5 |
cytotoxic edema | 5 |
admission characteristics | 5 |
days prior | 5 |
randomized trials | 5 |
increased rate | 5 |
encourage patients | 5 |
alberta stroke | 5 |
higher nihss | 5 |
artery stenosis | 5 |
mr perfusion | 5 |
hospital stroke | 5 |
outcomes related | 5 |
care team | 5 |
injury may | 5 |
oxygen delivery | 5 |
study demonstrated | 5 |
lmwh group | 5 |
endothelial activation | 5 |
clinical setting | 5 |
serious adverse | 5 |
alzheimer disease | 5 |
intracerebral hematoma | 5 |
icu care | 5 |
triangle mesh | 5 |
clinical symptoms | 5 |
intraventricular alteplase | 5 |
modified fisher | 5 |
randomized trial | 5 |
received continuous | 5 |
clonic seizures | 5 |
developed dci | 5 |
statistical tests | 5 |
covid pandemic | 5 |
nt group | 5 |
patient age | 5 |
death examination | 5 |
prior diagnosis | 5 |
trauma patients | 5 |
forelimb muscles | 5 |
trauma centers | 5 |
nt entered | 5 |
thromboembolic event | 5 |
adapted asu | 5 |
radiographic findings | 5 |
icp spikes | 5 |
stroke complications | 5 |
organ function | 5 |
mri findings | 5 |
also associated | 5 |
increased intracranial | 5 |
compared patients | 5 |
pulmonary complications | 5 |
tertiary medical | 5 |
cells transplanted | 5 |
right eye | 5 |
tertiary center | 5 |
will likely | 5 |
positive end | 5 |
nuclear scintigraphy | 5 |
coagulation system | 5 |
study conducted | 5 |
patients due | 5 |
iv antihypertensive | 5 |
hospital death | 5 |
may worsen | 5 |
period i | 5 |
expiratory pressure | 5 |
treated side | 5 |
cerebellar edema | 5 |
stroke acute | 5 |
cortical injury | 5 |
characteristics including | 5 |
radiographic features | 5 |
early detection | 5 |
care delivery | 5 |
sectional study | 5 |
nasopharyngeal swab | 5 |
case demonstrates | 5 |
effective treatment | 5 |
post procedure | 5 |
patient suffered | 5 |
affected side | 5 |
minutes later | 5 |
replacement therapy | 5 |
approximately half | 5 |
airway pressure | 5 |
neurologic complications | 5 |
impaired consciousness | 5 |
vessel wall | 5 |
hours later | 5 |
porcine model | 5 |
period iv | 5 |
short period | 5 |
mri scan | 5 |
rotterdam score | 5 |
ventilatory support | 5 |
treated groups | 5 |
median values | 5 |
stroke chain | 5 |
free fraction | 5 |
loyola university | 5 |
rare complication | 5 |
ttm group | 5 |
ionic contrast | 5 |
brain function | 5 |
acute cerebral | 5 |
eff ect | 5 |
significant due | 5 |
many studies | 5 |
forward translation | 5 |
catheterization laboratory | 5 |
virtual reality | 5 |
lobar ich | 5 |
transverse sinus | 5 |
artery aneurysm | 5 |
artery dissection | 5 |
ih therapy | 5 |
mca stroke | 5 |
downward trend | 5 |
chosen based | 5 |
modafinil administration | 5 |
ancillary testing | 5 |
time sensitive | 5 |
diastolic bp | 5 |
investigate whether | 5 |
occipital lobe | 5 |
cta spot | 5 |
doppler ultrasound | 5 |
high cost | 5 |
previous work | 5 |
also contribute | 5 |
showed extensive | 5 |
female presented | 5 |
neurologic deficits | 5 |
vs patients | 5 |
ncc qi | 5 |
department visits | 5 |
better outcomes | 5 |
became unresponsive | 5 |
california hospitals | 5 |
rna sequencing | 5 |
lesion location | 5 |
epidemiological weeks | 5 |
investigated using | 5 |
characteristics included | 5 |
complete recovery | 5 |
extracorporeal membrane | 5 |
spg blockade | 5 |
comfort level | 5 |
ceribell system | 5 |
using one | 5 |
ceegm headset | 5 |
may facilitate | 5 |
study examined | 5 |
developed new | 5 |
also measured | 5 |
care pathways | 5 |
incidence study | 5 |
select patients | 5 |
clinical information | 5 |
mashhad stroke | 5 |
also higher | 5 |
consecutive series | 5 |
urine output | 5 |
evaluated using | 5 |
acute renal | 5 |
recombinant human | 5 |
south korea | 5 |
pearson correlation | 5 |
respirasome stability | 5 |
local organ | 5 |
following traumatic | 5 |
reduce mortality | 5 |
ischemic injuries | 5 |
receiving amantadine | 5 |
circulation stroke | 5 |
vessels occlusion | 5 |
inflammatory markers | 5 |
severe neurological | 5 |
chronic health | 5 |
endotracheal tube | 5 |
tertiary hospital | 5 |
free projection | 5 |
four days | 5 |
default mode | 5 |
available literature | 5 |
eeg reactivity | 5 |
open access | 5 |
lateralized rhythmic | 5 |
stroke survivors | 5 |
reperfusion injury | 5 |
diagnostic criteria | 5 |
ace receptors | 5 |
well known | 5 |
valproic acid | 5 |
peripheral immune | 5 |
improves functional | 5 |
thermal conductivity | 5 |
head computed | 5 |
milder stroke | 5 |
treatment time | 5 |
unclear whether | 5 |
received andexanet | 5 |
primary outcomes | 5 |
qi program | 5 |
despite treatment | 5 |
vs without | 5 |
propensity score | 5 |
underwent endovascular | 5 |
sensitivity analysis | 5 |
model using | 5 |
upper extremity | 5 |
usual care | 5 |
type i | 5 |
angiotensin converting | 5 |
multicenter study | 5 |
age group | 5 |
hours prior | 5 |
human mesenchymal | 5 |
ed frequency | 5 |
referral center | 5 |
data suggests | 5 |
spontaneous resolution | 5 |
ica aneurysms | 5 |
random effects | 5 |
current clinical | 5 |
two years | 5 |
less common | 5 |
median door | 5 |
effectiveness analysis | 5 |
tbi models | 5 |
comatose cardiac | 5 |
considered significant | 5 |
guided piv | 5 |
iii scores | 5 |
di culty | 5 |
aneurysm instability | 5 |
acute coronary | 5 |
search terms | 5 |
woman presented | 5 |
may explain | 5 |
care due | 5 |
case studies | 5 |
hours despite | 5 |
seeking medical | 5 |
heat shock | 5 |
selected patients | 5 |
way anova | 5 |
stroke hospitalizations | 5 |
received therapeutic | 5 |
underwent surgical | 5 |
nadroparin calcium | 5 |
venous catheters | 5 |
care services | 5 |
using icd | 5 |
operating characteristic | 5 |
transthoracic echocardiography | 5 |
cognitive reserve | 5 |
symptoms like | 5 |
external triggering | 5 |
hospitals across | 5 |
vte rate | 5 |
mild covid | 5 |
clinical diagnosis | 5 |
possible cause | 5 |
protocol adherence | 5 |
loading dose | 5 |
impregnated catheters | 5 |
death exam | 5 |
interrupted time | 5 |
administration may | 5 |
stroke rats | 5 |
survey respondents | 5 |
times per | 5 |
asu care | 5 |
stroke presentation | 5 |
reduced infarct | 5 |
bystander cpr | 5 |
johns hopkins | 5 |
final diagnosis | 5 |
high degree | 5 |
glucose deprivation | 5 |
bayesian hierarchical | 5 |
human trials | 5 |
translation approach | 5 |
adult neural | 5 |
first seizure | 5 |
task force | 5 |
valiasr hospital | 5 |
thrombotic event | 5 |
acute rehab | 5 |
showed bilateral | 5 |
occipital lobes | 5 |
stroke statistics | 5 |
derived neurotrophic | 5 |
translational genomic | 5 |
four hours | 5 |
water content | 5 |
rate variability | 5 |
lower extremity | 5 |
patient became | 5 |
control groups | 5 |
computed using | 5 |
mri showed | 5 |
parallel surface | 5 |
elderly rats | 5 |
cell derived | 5 |
cardiovascular system | 5 |
reasonable request | 5 |
among different | 5 |
new process | 5 |
present two | 5 |
care center | 5 |
antibiotic prophylaxis | 5 |
disease risk | 5 |
decision trees | 5 |
somewhat comfortable | 5 |
patient continued | 5 |
surgical procedures | 5 |
predicted poor | 5 |
ischaemic attack | 5 |
object surface | 5 |
may induce | 5 |
ct perfusion | 5 |
attending physicians | 5 |
using multiple | 5 |
apache iv | 5 |
muscle spindles | 5 |
near infrared | 5 |
eye opening | 5 |
poor grade | 5 |
zanjan province | 5 |
epithelial cells | 5 |
midazolam infusion | 5 |
inflammatory factors | 5 |
large academic | 5 |
collateral status | 5 |
determined using | 5 |
personal protection | 5 |
factors included | 5 |
angiographic vasospasm | 5 |
arterial hypertension | 5 |
prisma guidelines | 5 |
academic center | 5 |
established stroke | 5 |
neuro intensive | 5 |
aneurysm repair | 5 |
minutes versus | 5 |
laboratory tests | 5 |
minor strokes | 5 |
without significant | 5 |
blood platelets | 5 |
antithrombotic agents | 5 |
index hospitalization | 5 |
odca patients | 5 |
hess score | 5 |
brain magnetic | 5 |
drug intoxication | 5 |
cardiac surgery | 5 |
system resources | 5 |
continuous electroencephalogram | 5 |
care workers | 5 |
seven patients | 5 |
advanced practice | 5 |
antibiotics group | 5 |
preliminary analysis | 5 |
mean hospital | 5 |
dai grade | 5 |
vascular diseases | 5 |
hemorrhage expansion | 5 |
cell mobilization | 5 |
differential diagnosis | 5 |
ii scores | 5 |
care transport | 5 |
interim analysis | 5 |
ventilator days | 5 |
global world | 5 |
health emergency | 5 |
university medical | 5 |
following cas | 5 |
background deterioration | 5 |
severe coronavirus | 5 |
well studied | 5 |
right middle | 5 |
continuous infusions | 5 |
final follow | 5 |
cerebral glucose | 5 |
intended curve | 5 |
physical therapy | 5 |
itd use | 5 |
infectious diarrhea | 5 |
tested positive | 5 |
older adults | 5 |
cerebral salt | 5 |
bedside tool | 5 |
baylor st | 5 |
ordinal logistic | 5 |
center cohort | 5 |
xa level | 5 |
april th | 5 |
mean temperature | 5 |
study performed | 5 |
evd go | 5 |
microvascular thrombosis | 5 |
study included | 5 |
neurological patients | 5 |
gene modification | 5 |
patients managed | 5 |
hemorrhagic conversion | 5 |
stroke trial | 5 |
hospitalization rate | 5 |
right hemiparesis | 5 |
soft tissue | 5 |
identify predictors | 5 |
pressure reactivity | 5 |
go bag | 5 |
genomic research | 5 |
pg ml | 5 |
iii trial | 5 |
drawn within | 5 |
using standardized | 5 |
autoimmune encephalitis | 5 |
pandemic period | 5 |
delayed presentation | 5 |
antihypertensive infusion | 5 |
conventional angiography | 5 |
structured rounding | 5 |
currently available | 5 |
levels drawn | 5 |
texture synthesis | 5 |
nursing staff | 5 |
injury severity | 5 |
ray direction | 5 |
pupillometry provides | 5 |
mortality due | 5 |
stroke secondary | 5 |
standard treatment | 5 |
underlying mechanisms | 5 |
physical exam | 5 |
vertical cylinder | 5 |
practice providers | 5 |